Approximately 7500 specialists from across the world met in Copenhagen, Denmark at EAACI 2014, the world’s leading medical congress on allergy and immunology, to discuss recent... [leer más]
Japan is the world’s largest market for antihistamines; sales are higher than in Europe.
Rupatadine, one of Uriach’s star products, will be launched on the Japanese market in the next four... [leer más]
Uriach Group EBITDA grew by 100% compared to the previous year, going from 10 to 20 million euros. This was achieved by aligning the activity of its four strategic business areas: OTC and Natural Care, Generics, Pharma Licensing and Contract Manufacturing.[leer más]